Macquarie Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Macquarie Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,499	Closed	-$32K	–	2314
2017 Q4	$32K	Buy	+3,499	New	+$33.5K	﹤0.01%	2108

Other funds holding ORMP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

RPC

Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Macquarie Group's ORMP Position: Q1 2018 in Review

Macquarie Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2018, closing a stake of 3,499 shares — an estimated $32K sold.

Macquarie Group first reported a position in ORMP in Q4 2017 and held it in 1 quarter. The position peaked at $32K in Q4 2017. 21 funds tracked by Wall St. Rank hold ORMP as of Q1 2018.

Macquarie Group reported no remaining Oramed Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 3,499 Oramed Pharmaceuticals shares in Q1 2018, an estimated $32K.
Macquarie Group first reported a position in Oramed Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Macquarie Group's Oramed Pharmaceuticals position peaked at $32K in Q4 2017.
21 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.